专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US08410094B2 Amide compounds, their pharmaceutical compositions, their preparation method and their uses 有权
标题翻译：酰胺化合物，其药物组合物，其制备方法及其用途
公开(公告)号：US08410094B2
公开(公告)日：2013-04-02
申请号：US13123455
申请日：2009-09-18
申请人： Yaqiu Long , Xing Fan , Dongzhi Feng , Li Chen , Renhai Chen
发明人： Yaqiu Long , Xing Fan , Dongzhi Feng , Li Chen , Renhai Chen
IPC分类号： C07D451/04 , A61K31/46
CPC分类号： C07D451/04
摘要： The present invention pertains to the field of pharmaceutical chemistry and discloses 8-(3-aminopropyl)-3-exo-8-azabicyclo[3.2.1]octane-3-amino amide compounds represented by formula I, the pharmaceutical compositions, the preparation method and the use thereof. Such compounds or pharmaceutically acceptable salts thereof can be used as an antagonist of CCR5 in preparing medicaments for treating diseases mediated by CCR5, particularly HIV infection, asthma, rheumatoid arthritis, autoimmune diseases and chronic obstructive pulmonary diseases (COPD).
摘要翻译：本发明涉及药物化学领域，并公开了由式I表示的8-（3-氨基丙基）-3-外-8-氮杂双环[3.2.1]辛烷-3-氨基酰胺化合物，药物组合物，制剂方法及其用途。这些化合物或其药学上可接受的盐可用作CCR5拮抗剂，用于制备用于治疗由CCR5介导的疾病，特别是HIV感染，哮喘，类风湿性关节炎，自身免疫疾病和慢性阻塞性肺疾病（COPD）介导的疾病。

42. 发明申请

US20120231537A1 Highly Pure Plasmid DNA Preparations 审中-公开
标题翻译：高纯度质粒DNA制剂
公开(公告)号：US20120231537A1
公开(公告)日：2012-09-13
申请号：US13431359
申请日：2012-03-27
申请人： Nancy Smyth Templeton , Li Chen
发明人： Nancy Smyth Templeton , Li Chen
IPC分类号： C12N15/63
CPC分类号： C12N15/1003 , C12N15/101 , C12N15/1017
摘要： The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that comprises purifying plasmid DNA by chromatography, treating the purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colonic acid, and separating the plasmid DNA from the digested colonic acid.
摘要翻译：本公开内容通常涉及具有低或不可检测水平的高聚糖酸和其它污染物的高纯度质粒组合物，其通过以下方法制备，所述方法包括通过色谱法纯化质粒DNA，用在多唾液酸中消化的多肽处理纯化的质粒DNA，消化结肠酸，并从消化的结肠酸分离质粒DNA。

43. 发明申请

US20120188886A1 Allocation Method for Physical Downlink Control Channel, Base Station and User Terminal 有权
标题翻译：物理下行链路控制信道，基站和用户终端的分配方法
公开(公告)号：US20120188886A1
公开(公告)日：2012-07-26
申请号：US13145746
申请日：2010-01-14
申请人： Li Chen , Zhuo Gao , Guooing Li
发明人： Li Chen , Zhuo Gao , Guooing Li
IPC分类号： H04W24/00 , H04W72/04
CPC分类号： H04W72/042 , H04L5/001 , H04L5/0096 , H04L5/0098 , H04W24/00 , H04W52/0229 , H04W68/00 , H04W72/0453 , H04W72/1289 , Y02D70/00 , Y02D70/1262 , Y02D70/1264
摘要： The present invention discloses a method for configuring a Physical Downlink Control Channel (PDCCH), a base station and a UE, wherein the base station configures a component carrier or component carriers for monitoring the PDCCH for the UE and notifies the UE about information on the configured component carrier or component carriers so that the UE monitors the PDCCH only over the configured component carrier or component carriers. Stated otherwise, in this way, the UE will operate only over a necessary component carrier or component carriers without monitoring respective component carriers in an LTE-A system to thereby reduce the number of concurrently monitored component carriers, and in the case of nonconsecutive component carriers, also reduce the number of consequently enabled receivers and consequently the amount of consumed power of the UE for monitoring the PDCCH.
摘要翻译：本发明公开了一种用于配置物理下行链路控制信道（PDCCH），基站和UE的方法，其中基站配置用于监视用于UE的PDCCH的分量载波或分量载波，并且向UE通知关于配置的分量载波或分量载波，使得UE仅通过配置的分量载波或分量载波来监视PDCCH。否则，以这种方式，UE将仅在必需的分量载波或分量载波上操作，而不监视LTE-A系统中的相应分量载波，从而减少同时监视的分量载波的数量，并且在非连续分量载波的情况下，还减少因此启用的接收机的数量，并因此减少用于监视PDCCH的UE的消耗功率量。

44. 发明授权

US08222416B2 Azaindole glucokinase activators 有权
标题翻译： Azaindole葡糖激酶活化剂
公开(公告)号：US08222416B2
公开(公告)日：2012-07-17
申请号：US12943539
申请日：2010-11-10
申请人： Steven Joseph Berthel , Li Chen , Wendy Lea Corbett , Lichun Feng , Nancy-Ellen Haynes , Robert Francis Kester , Sung-Sau So , Jefferson Wright Tilley
发明人： Steven Joseph Berthel , Li Chen , Wendy Lea Corbett , Lichun Feng , Nancy-Ellen Haynes , Robert Francis Kester , Sung-Sau So , Jefferson Wright Tilley
IPC分类号： C07D471/02 , A61K31/545
CPC分类号： C07D471/04 , C07C2601/04 , C07C2601/06 , C07D401/06 , C07D403/10 , C07D405/06
摘要： Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
摘要翻译：本文提供式（I）的化合物及其药学上可接受的盐，其中取代基如说明书中公开的那些。这些化合物和含有它们的药物组合物可用于治疗代谢疾病和病症，例如II型糖尿病。

45. 发明申请

US20120147755A1 METHOD AND DEVICE FOR JUDGING RADIO LINK FAILURE IN CARRIER AGGREGATION TECHNOLOGY 有权
标题翻译：用于判断载波聚合技术中无线链路故障的方法和装置
公开(公告)号：US20120147755A1
公开(公告)日：2012-06-14
申请号：US13390332
申请日：2010-08-13
申请人： Li Chen , Jiamin Liu , Jing Liang
发明人： Li Chen , Jiamin Liu , Jing Liang
IPC分类号： H04L12/26 , H04W24/00
CPC分类号： H04W24/08 , H04L5/001 , H04L5/005 , H04L25/0208 , H04W24/10 , H04W52/0216 , H04W76/18 , H04W76/19
摘要： The present invention discloses a method and device for judging Radio Link Failure (RLF) in Carrier Aggregation (CA) technology, which are used to effectively judge whether a radio link is failed or not in CA technology. Said method comprises: on an evaluation point, comparing the determined radio link quality parameter of each carrier participating in the RLF judgement with the corresponding radio link quality parameter threshold, determining whether to trigger an in-sync indication or out-of-sync indication on the evaluation point, and judging whether the radio link of the User Equipment (UE) is failed according to the number of the continuously received in-sync indications or out-of-sync indications. The embodiment of the present invention determines whether to trigger an in-sync indication or out-of-sync indication by comparing the radio link quality parameters of the carriers participating in the RLF judgement with the corresponding radio link quality parameter thresholds, and thereby judges that whether the radio link is failed or not in CA technology.
摘要翻译：本发明公开了一种用于在CA技术中判断无线链路是否失败的载波聚合（CA）技术中的无线链路故障（RLF）的方法和装置。所述方法包括：在评估点上，将参与RLF判断的每个载波的所确定的无线电链路质量参数与对应的无线电链路质量参数阈值进行比较，确定是否触发同步指示或不同步指示评估点，并且根据连续接收到的同步指示或不同步指示的数量来判断用户设备（UE）的无线链路是否失败。本发明的实施例通过将参与RLF判断的载波的无线电链路质量参数与对应的无线电链路质量参数阈值进行比较，来确定是否触发同步指示或不同步指示，从而判断该无线电链路在CA技术中是否失败。

46. 发明申请

US20120113811A1 METHOD, SYSTEM AND APPARATUS FOR NOTIFYING A UE OF MONITORED COMPONENT CARRIERS 有权
标题翻译：用于通知监控组件载波的UE的方法，系统和装置
公开(公告)号：US20120113811A1
公开(公告)日：2012-05-10
申请号：US13266758
申请日：2010-04-23
申请人： Wei Bao , Li Chen , Guoqing Li
发明人： Wei Bao , Li Chen , Guoqing Li
IPC分类号： H04W24/00
CPC分类号： H04L5/001 , H04L5/0053 , H04L5/0098 , H04W24/00
摘要： The present invention provides a method for notifying a UE of monitored component carriers. The method comprises the following steps: an evolved Node B (eNB) sends an monitoring changing instruction and Component Carriers (CC) corresponding to the instruction to a UE with a Media Access Control (MAC) layer control command; according to the monitoring changing instruction and the corresponding CC, the UE activates or deactivates monitoring of the corresponding CC. The present invention allows the MAC PDU for instructing the UE to increase, decrease or change the monitored CC. Therefore, the configuration can be achieved in a simple and flexible manner and has higher reliability.
摘要翻译：本发明提供了一种通知UE监视的分量载波的方法。该方法包括以下步骤：演进节点B（eNB）使用媒体接入控制（MAC）层控制命令向UE发送与该指令相对应的监视改变指令和分量载波（CC）; 根据监控变更指令和相应的CC，UE激活或关闭相应CC的监控。本发明允许MAC PDU指示UE增加，减少或改变所监视的CC。因此，可以简单灵活地实现配置，具有更高的可靠性。

47. 发明授权

US08162480B2 Systems and software for wavefront data processing, vision correction, and other applications 有权
标题翻译：用于波前数据处理，视力矫正和其他应用的系统和软件
公开(公告)号：US08162480B2
公开(公告)日：2012-04-24
申请号：US12650130
申请日：2009-12-30
申请人： Huawei Zhao , Li Chen
发明人： Huawei Zhao , Li Chen
IPC分类号： A61B3/10
CPC分类号： A61B3/1015
摘要： A system for providing vision contains an aberrometer, a wavefront sensor, and a transfer optical system. The aberrometer is configured to measure a received wavefront. The aberrometer includes a wavefront sensor and a transfer optical system for transferring an input wavefront so as to the provide the received wavefront at or near the wavefront sensor. The system also includes a processor in communication with the aberrometer, a readable memory, and instructions located within the memory. The readable memory contains one or more system error parameters and instructions for calculating the input wavefront based on the received wavefront and the one or more system error parameters.
摘要翻译：用于提供视觉的系统包括像差计，波前传感器和传输光学系统。像差计被配置为测量接收的波前。像差仪包括波前传感器和用于传送输入波前的传输光学系统，以便在波前传感器处或附近提供接收的波前。该系统还包括与像差计的通信处理器，可读存储器和位于存储器内的指令。可读存储器包含一个或多个系统错误参数和用于基于接收的波阵面和一个或多个系统错误参数计算输入波前的指令。

48. 发明授权

US08119644B2 Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists 有权
标题翻译：噻二唑取代的芳酰胺如P2X3和P2X2 / 3拮抗剂
公开(公告)号：US08119644B2
公开(公告)日：2012-02-21
申请号：US12636723
申请日：2009-12-12
申请人： Li Chen , Lichun Feng , Minmin Yang , Michael Patrick Dillon , Yingjie Lai
发明人： Li Chen , Lichun Feng , Minmin Yang , Michael Patrick Dillon , Yingjie Lai
IPC分类号： A61K31/444 , A61K31/497 , A61K31/433 , A61P13/00 , A61P13/10 , A61P25/00 , C07D417/14 , C07D285/06
CPC分类号： C07D417/14 , A61K31/166 , A61K31/433 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/497 , C07D285/06 , C07D417/12
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译：式I化合物或其药学上可接受的盐，其中R 1为任选取代的噻二唑基，R 2，R 3，R 4，R 5，R 6，R 7和R 8如本文所定义。还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。

49. 发明授权

US08093275B2 Oxazolone and pyrrolidinone-substituted pryidine amides as P2X3 and P2X2/3 antagonists 有权
标题翻译：恶唑酮和吡咯烷酮取代的Pryidine酰胺作为P2X3和P2X2 / 3拮抗剂
公开(公告)号：US08093275B2
公开(公告)日：2012-01-10
申请号：US12820660
申请日：2010-06-22
申请人： Li Chen , Michael Patrick Dillon , Lichun Feng , Minmin Yang
发明人： Li Chen , Michael Patrick Dillon , Lichun Feng , Minmin Yang
IPC分类号： A61K31/44
CPC分类号： A61K31/497 , C07D207/27 , C07D233/32 , C07D263/20 , C07D401/14 , C07D403/12 , C07D407/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D473/00
摘要： Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
摘要翻译：式I化合物或其药学上可接受的盐，其中X，Y，R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义。还公开了使用该化合物治疗与P2X3和/或P2X2 / 3受体拮抗剂相关疾病的方法和制备该化合物的方法。

50. 发明申请

US20120004218A1 NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES 失效
标题翻译：新型四氢喹啉衍生物
公开(公告)号：US20120004218A1
公开(公告)日：2012-01-05
申请号：US13169097
申请日：2011-06-27
申请人： Li Chen , Lichun Feng , Yun He , Mengwei Huang , Yongfu Liu , Hongying Yun , Mingwei Zhou
发明人： Li Chen , Lichun Feng , Yun He , Mengwei Huang , Yongfu Liu , Hongying Yun , Mingwei Zhou
IPC分类号： A61K31/541 , C07D215/48 , C07D413/10 , C07D401/10 , C07D471/04 , C07D405/10 , C07D417/14 , A61K31/4747 , A61K31/47 , A61K31/5377 , A61K31/496 , A61K31/4375 , A61P3/04 , A61P3/10 , A61P35/00 , A61P3/06 , C07D221/20
CPC分类号： C07D215/48 , C07D401/06 , C07D405/12 , C07D471/04
摘要： A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A1 to A3 and R1 to R10 have the significance given in claim 1, can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.
摘要翻译：式（I）化合物或其药学上可接受的盐或酯，其中A1至A3和R1至R10具有权利要求1中给出的含义，可用作药物。这些化合物可用于治疗或预防与AMPK调节相关的疾病，例如肥胖症，血脂异常，高血糖症，1型或2型糖尿病和癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式